CLINICIANS
CLINICAL APPLICATIONS & FURTHER READING
Revita , scientific and clinical evidence
®
Revita is an intact human placental membrane allograft that preserves all layers of the biologic tissue and maintains the physiologic 3D architecture of the natural barrier membrane.
Intact Human Placental Membrane vs. Dehydrated Competitor
Revita preserves all three layers of the amniotic membrane architecture.
Unprocessed placental membrane
Revita preservation of 3D architecture
Competitor
Revita provides the complete intact human placental membrane that is the physiologic tissue carrier naturally found in the body.
This complete membrane containing amnion, intermediate layer and chorion retains many of the cytokines and growth factors the body uses to heal, protect and grow tissues.
CLINICAL APPLICATIONS INCLUDE:
Wound Care
-
Diabetic Wounds
-
Venous / Arterial Ulcers
-
Pressure Ulcers
-
Burn Wounds
-
Plastic Surgery
PRESERVATION OF THE INTERMEDIATE LAYER
The amniotic intermediate layer is a vital part of the membrane barrier present between the amnion and chorion layers
THE INTERMEDIATE LAYER:
-
Acts as a cushion
-
Contains Hyaluronic Acid (HA) + Collagen
-
Contains growth factors
-
Contains Glycosaminoglycans and Proteoglycans
CASE STUDY - Revita Clinical Application: Challenging Chronic Wound
®
Day 0 Wound
![Challenging Chronic Wound[1].png](https://static.wixstatic.com/media/434c6e_3f4b961ec59c4c66aeb9d35c979217f3~mv2.png/v1/crop/x_0,y_165,w_513,h_781/fill/w_52,h_80,al_c,q_85,usm_0.66_1.00_0.01,blur_2,enc_auto/Challenging%20Chronic%20Wound%5B1%5D.png)
Day 0 Application
![Challenging Chronic Wound[1].png](https://static.wixstatic.com/media/434c6e_3f4b961ec59c4c66aeb9d35c979217f3~mv2.png/v1/crop/x_577,y_165,w_513,h_781/fill/w_52,h_80,al_c,q_85,usm_0.66_1.00_0.01,blur_2,enc_auto/Challenging%20Chronic%20Wound%5B1%5D.png)
Day 41
![Challenging Chronic Wound[1].png](https://static.wixstatic.com/media/434c6e_3f4b961ec59c4c66aeb9d35c979217f3~mv2.png/v1/crop/x_1161,y_165,w_513,h_781/fill/w_52,h_80,al_c,q_85,usm_0.66_1.00_0.01,blur_2,enc_auto/Challenging%20Chronic%20Wound%5B1%5D.png)
95% Closure
![Challenging Chronic Wound[1].png](https://static.wixstatic.com/media/434c6e_3f4b961ec59c4c66aeb9d35c979217f3~mv2.png/v1/crop/x_1737,y_165,w_513,h_781/fill/w_52,h_80,al_c,q_85,usm_0.66_1.00_0.01,blur_2,enc_auto/Challenging%20Chronic%20Wound%5B1%5D.png)
Introduction
The patient in this case study was selected to evaluate this exceptional product capacity in a notably challenging clinical application. The patient, an elderly woman with multiple comorbidities and existing amputations, presented with a deep venous leg ulcer that consistently failed other treatments. Her case is presented here.
Initial Patient Evaluation and Product Application: Day 0
87-year-old female presented with a severe venous leg ulcer (VLU) on her lower right leg measuring 11 cm in length and 4 cm in width with exposed tendon and heavy exudate of purulent consistency. Conservative therapies were previously attempted for months without success.
The patient had a history of diabetes and smoking, and all toes had previously been amputated. She also reported a high pain level of 8 on a Visual Analog Scale (VAS) of 1 to 10 at the site of the VLU.
At the time of initial evaluation, the wound was cleaned and five Revita allografts were used to cover the wound.
Standard facility protocol for tissue application was followed, including placement of a non-adherent hydrogel for protection. Clinicians rated the ease of Revita application as excellent.
Follow Up: Day 27
The wound was cleaned, debrided, and clinicians re-applied five Revita allografts. Clinicians rated the ease of Revita application as excellent.
Follow Up: Day 41
Clinicians noted “good results” with healthy tissue developing around the previously exposed tendon. The wound was cleaned, debrided, and clinicians re-applied four Revita allografts.
Final Treatment: Day 62
Clinicians noted a “considerable improvement” with low exudate levels and healthy tissue development and reapplied three Revita allografts to continue treatment.
Wound Resolution
Wound continued to progress through to closure with “incredible results” noted by the clinicians.
Further Readings
REVITA SCIENTIFIC AND CLINICAL COMPENDIUM
- Stimlabs LLC
BIBLIOGRAPHY OF AMNIOTIC MEMBRANE TECHNOLOGY_2016 - Stimlabs LLC
REVITA A DERMATOLOGICAL EXCISION DEFECT CASE REPORT - Dr Callaway
CLINICAL LITERATURE REVIEW - Tony Parker, PhD
THE USE OF A REVITA ALLOGRAFT FOR WOUND BED PREPARATION IN A TRAUMA INDUCED WOUND - Dr Sharif
Our new Brisbane based advanced manufacturing facility is licensed by the TGA to manufacture Revita for clinical use in Australia.
(Licence # MI-2018-LI-13190-1)
Revita is registered on the Australian Register of Therapeutic Goods (ARTG Entry # 350670)
Revita is available to order through our distribution partners CuraTech P/L
®
Mike and Roger co-founded CuraTech Pty Ltd in August 2023 to enter into a distribution agreement for Australia and New Zealand with SurgicalBioFix.
They are establishing a network of agents/distributors to supply the community with Revita .
Contacts: info@curatech.com.au
®
Mike Wollert began his career in the medical industry with Arrow Pharmaceuticals in 2005 before making the transition to orthopaedics with Zimmer in 2010. Following nearly six years of successful service, he accepted a position at Mathys Orthopaedics, where he achieved double-digit growth year over year. In 2023, he left the company to pursue his dream of starting his own business.
Throughout his various positions in orthopaedics, he has honed skills in clinical support, sales, marketing, and management. He is very experienced in hip, knee, and shoulder arthroplasty, including revision surgery. Mike takes a hands-on approach to life and enjoys immersing himself in diverse areas of interest.
+61 439 088 320
Roger Baumgartner made his first experience with wound care in 1995 when joining Smith & Nephew in Switzerland. In 2001 he joined Mathys as an international product manager responsible for building a shoulder replacement portfolio before moving to Australia in December 2012 with his family to oversee the Australian and New Zealand business as well as China and Japan for a few years as well. Leaving Mathys/Enovis in December 2022 he started his own business, graduated at the Australian Institute as Company Director and joined Bonebridge AG in October 2023 to establish and manage their subsidiaries in Australia/New Zealand.
+61 408 868 409